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Epilepsy is a chronic medical condition that still poses a challenge
in terms of treatment. There are a variety of anticonvulsants avail-
able today, but these do not prevent frequent hospital admissions
and emergency room visits. Benzodiazepines, however, remain the
first line treatment in acute seizure management. The approval
of phenytoin, fosphenytoin, intravenous valproate, and rectal
diazepam has given more options to the physicians for acute man-
agement. The approval of intravenous levetiracetam has provided
another option for physicians with patients who failed the other
approved anticonvulsants. Intravenous levetiracetam is approved
for patients 4 years and older as an alternative to oral treatment.
There have been various case reports, case series, and retrospective
studies showing the efficacy of intravenous levetiracetam both in
status epilepticus (SE) and acute seizure exacerbation. These stud-
ies reported favorable response of intravenous levetiracetam in
both adults and children. Data have even shown good results in
neonates and preterm children. In this volume, we have included
articles from renowned researchers in the field of neurology and
epilepsy who have covered the various aspects of these agents
in detail including the properties, mechanism of action, phar-
macology, neurobehavioral effects, and the roles of these agents
in special populations. These data further show that intravenous
levetiracetam can be used in acute seizure management.
This book opens with a chapter by Jennifer L. DeWolfe and Jerzy
P. Szaflarski (1) that discusses in detail the role of intravenous
levetiracetam in the critical care setting. The literature review
was conducted, which showed that intravenous levetiracetam is
effective in terminating different types of seizures including SE,
post-traumatic and tumor-related seizures, seizures due to stroke,
and intraparenchymal hemorrhage. The pharmacokinetics of this
agent in special populations including elderly, pregnant, and neu-
rocritical patients is also discussed in this chapter. The authors
concluded that there is still need for larger prospective trials, but
based on current data, the drug appears to be safe and better
tolerated in different subgroups of seizure population. The sec-
ond chapter by Wright et al. (2) reviewed the current literature
about the pharmacology and pharmacokinetics of intravenous
levetiracetam and the safety profile of this drug in adults and
children. The article also showed unique mechanism of action,
linear pharmacokinetics, and no known drug–drug interactions
with other anticonvulsants, which makes it a viable option for
acute seizure management in both adults and children. The third
chapter by Aceves et al. (3) further discusses in detail the current
data regarding the safety and tolerability of intravenous levetirac-
etam in children and neonates in the management of SE and acute
repetitive seizures. The authors also emphasize the need for a larger
prospective multicenter trial to further define the roles of these
anticonvulsants in this population subgroup.
Status epilepticus is a major neurological emergency that is
associated with high morbidity and mortality. SE can cause sig-
nificant neuronal injury and the patients who survive SE develop
long term neurological sequelae including major cognitive issues.
The fourth chapter is by Laxmikant S. Deshpande and Robert J.
DeLorenzo who discuss the mechanisms of levetiracetam in the
control of SE and epilepsy. (4) The authors in their review focused
on the unique anticonvulsant properties of levetiracetam and con-
cluded that the unconventional mechanism of action, favorable
safety profile, and lack of sedating effects makes it a viable candi-
date to be used in the management of this neurological emergency.
The fifth chapter by Hae Won Shin and Robin Davis is the review
of levetiracetam as a first line treatment in SE in adult patients and
the need for larger prospective trials in the future (5).
The sixth chapter by Fonkem et al. (6) and seventh chapter by
Bernett et al. (7) focus on a special population subgroup – those
with brain tumor-related seizures. Fonkem et al. (6) in his liter-
ature review article has shown that levetiracetam is an attractive
option for brain tumor-related seizures because levetiracetam can
increase the sensitivity of glioblastoma tumors to the chemother-
apy drug temozolomide. Levetiracetam can also be used as pro-
phylaxis in patients with brain tumors and in patients undergoing
neurological surgery. Bernett et al. (7) summarize the limited data
available, which show the potential risk of neurobehavioral side-
effects with levetiracetam in brain tumor-related seizure patients
and the need for future research.
The next four chapters focus on traumatic brain injury and the
neuroprotective properties of Levetiracetam. The eighth chapter
by Shetty et al. (8) discusses in detail the data available about the
potential mechanism of epileptogenesis and neuroprotective prop-
erties of this agent, which are beneficial in treating seizures asso-
ciated with neurological conditions like SE, stroke, and traumatic
brain injury. The ninth chapter by Kovacs et al. (9) discusses the
blast traumatic brain injury models, neuropathology, and impli-
cations for seizure risk. In this review, the authors reviewed the
pathological results, which also included immunohistochemical
and special staining approaches from recent preclinical explo-
sive blast studies to better understand the mechanism by which
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explosions cause brain injury. This is followed by chapter by
Kirmani et al. (10), which discusses the role of intravenous lev-
etiracetam in severe traumatic brain injury patients. The authors
concluded, based on current literature review, that intravenous
levetiracetam can be considered as a viable option in acute care
settings if phenytoin is unavailable or the administration is not
feasible due to side-effects.
The next chapter by Benge et al. (11) summarizes the limited
current data available about the neurobehavioral effects of lev-
etiracetam in traumatic brain injury patients and the need for
future studies.
The last chapter is an original article by Rogers et al. (12)
in which effects of levetiracetam on the mitochondrial mem-
brane potential of neuronal and non-neuronal cells were exam-
ined in vitro to determine if levetiracetam influences meta-
bolic processes in these cell types. These results suggested that
both neuronal and non-neuronal anticonvulsant properties of
levetiracetam involve control over energy metabolism.
This book provides a comprehensive review of the role of intra-
venous levetiracetam in acute seizure management and empha-
sizes the need of larger prospective trials to further define the role
of this anticonvulsant.
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